A citation-based method for searching scientific literature

Debyani Chakravarty, Elmer Santos, Mabel Ryder, Jeffrey A Knauf, Xiao-Hui Liao, Brian L West, Gideon Bollag, Richard Kolesnick, Tin Htwe Thin, Neal Rosen, Pat Zanzonico, Steven M Larson, Samuel Refetoff, Ronald Ghossein, James A Fagin. J Clin Invest 2011
Times Cited: 235







List of co-cited articles
871 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
483
62


2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
44

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
S Michael Rothenberg, David G McFadden, Edwin L Palmer, Gilbert H Daniels, Lori J Wirth. Clin Cancer Res 2015
178
43

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
C Durante, N Haddy, E Baudin, S Leboulleux, D Hartl, J P Travagli, B Caillou, M Ricard, J D Lumbroso, F De Vathaire,[...]. J Clin Endocrinol Metab 2006
951
34

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Lara A Dunn, Eric J Sherman, Shrujal S Baxi, Vatche Tchekmedyian, Ravinder K Grewal, Steven M Larson, Keith S Pentlow, Sofia Haque, R Michael Tuttle, Mona M Sabra,[...]. J Clin Endocrinol Metab 2019
95
34

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
574
32

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
877
31

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
29

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.
James Nagarajah, Mina Le, Jeffrey A Knauf, Giuseppe Ferrandino, Cristina Montero-Conde, Nagavarakishore Pillarsetty, Alexander Bolaender, Christopher Irwin, Gnana Prakasam Krishnamoorthy, Mahesh Saqcena,[...]. J Clin Invest 2016
68
39

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
186
26

BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
C Durante, E Puxeddu, E Ferretti, R Morisi, S Moretti, R Bruno, F Barbi, N Avenia, A Scipioni, A Verrienti,[...]. J Clin Endocrinol Metab 2007
275
26


Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Tania Jaber, Steven G Waguespack, Maria E Cabanillas, Mohamed Elbanan, Thinh Vu, Ramona Dadu, Steven I Sherman, Moran Amit, Elmer B Santos, Mark Zafereo,[...]. J Clin Endocrinol Metab 2018
50
44

Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
431
21

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
385
21

Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Dingxie Liu, Shuiying Hu, Peng Hou, David Jiang, Stephen Condouris, Mingzhao Xing. Clin Cancer Res 2007
135
18

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
597
16

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, Michael Rivera, Adriana Heguy, Marc Ladanyi, Manickam Janakiraman, David Solit, Jeffrey A Knauf, R Michael Tuttle,[...]. Cancer Res 2009
372
14


Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
217
14

Definition and management of radioactive iodine-refractory differentiated thyroid cancer.
Martin Schlumberger, Marcia Brose, Rosella Elisei, Sophie Leboulleux, Markus Luster, Fabian Pitoia, Furio Pacini. Lancet Diabetes Endocrinol 2014
183
14

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.
Jeffrey A Knauf, Xiaolan Ma, Eric P Smith, Lei Zhang, Norisato Mitsutake, Xiao-Hui Liao, Samuel Refetoff, Yuri E Nikiforov, James A Fagin. Cancer Res 2005
310
14

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Gerald S Falchook, Michael Millward, David Hong, Aung Naing, Sarina Piha-Paul, Steven G Waguespack, Maria E Cabanillas, Steven I Sherman, Bo Ma, Martin Curtis,[...]. Thyroid 2015
128
13

The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Garcilaso Riesco-Eizaguirre, Irene Rodríguez, Antonio De la Vieja, Eugenia Costamagna, Nancy Carrasco, Manuel Nistal, Pilar Santisteban. Cancer Res 2009
199
12


BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
433
12

Thyroid cancer.
Maria E Cabanillas, David G McFadden, Cosimo Durante. Lancet 2016
647
12

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Maria E Cabanillas, Jonas A de Souza, Susan Geyer, Lori J Wirth, Michael E Menefee, Stephen V Liu, Komal Shah, John Wright, Manisha H Shah. J Clin Oncol 2017
75
16

Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
M M Sabra, J M Dominguez, R K Grewal, S M Larson, R A Ghossein, R M Tuttle, J A Fagin. J Clin Endocrinol Metab 2013
75
16

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.
Ian Ganly, Vladimir Makarov, Shyamprasad Deraje, YiYu Dong, Ed Reznik, Venkatraman Seshan, Gouri Nanjangud, Stephanie Eng, Promita Bose, Fengshen Kuo,[...]. Cancer Cell 2018
121
12

Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Amir Iravani, Benjamin Solomon, David A Pattison, Price Jackson, Aravind Ravi Kumar, Grace Kong, Michael S Hofman, Tim Akhurst, Rodney J Hicks. Thyroid 2019
38
31

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Kostandinos Sideras, John C Morris, Bryan McIver,[...]. Lancet Oncol 2010
308
11


Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
877
11

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
Cristina Montero-Conde, Sergio Ruiz-Llorente, Jose M Dominguez, Jeffrey A Knauf, Agnes Viale, Eric J Sherman, Mabel Ryder, Ronald A Ghossein, Neal Rosen, James A Fagin. Cancer Discov 2013
269
11

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
727
11

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.
Aime T Franco, Roberta Malaguarnera, Samuel Refetoff, Xiao-Hui Liao, Emma Lundsmith, Shioko Kimura, Catrin Pritchard, Richard Marais, Terry F Davies, Lee S Weinstein,[...]. Proc Natl Acad Sci U S A 2011
148
10

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardiere, Jan Tennvall, Ahmad Awada, José Manuel Gómez, Françoise Bonichon, Laurence Leenhardt, Christine Soufflet,[...]. Lancet Oncol 2012
244
10



Thyroid transcription factors in development, differentiation and disease.
Lara P Fernández, Arístides López-Márquez, Pilar Santisteban. Nat Rev Endocrinol 2015
136
10

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Glenn J Hanna, Naifa L Busaidy, Nicole G Chau, Lori J Wirth, Justine A Barletta, Antonio Calles, Robert I Haddad, Stefan Kraft, Maria E Cabanillas, Guilherme Rabinowits,[...]. Clin Cancer Res 2018
49
20

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
10

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
216
10

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
9

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Laurie L Carr, David A Mankoff, Bernardo H Goulart, Keith D Eaton, Peter T Capell, Elizabeth M Kell, Julie E Bauman, Renato G Martins. Clin Cancer Res 2010
287
9

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Iñigo Landa, Ian Ganly, Timothy A Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A Ghossein, James A Fagin. J Clin Endocrinol Metab 2013
283
9

Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
Christine Spitzweg, Keith C Bible, Lorenz C Hofbauer, John C Morris. Lancet Diabetes Endocrinol 2014
66
13

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
Richard J Robbins, Qiang Wan, Ravinder K Grewal, Roland Reibke, Mithat Gonen, H William Strauss, R Michael Tuttle, William Drucker, Steven M Larson. J Clin Endocrinol Metab 2006
361
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.